Samsara BioCapital GP, LLC

Samsara BioCapital GP, LLC bought 600,000 shares of MLYS at $13.50 on 2025-03-13, increasing holdings to 5,674,916 shares (+11.8%); cluster buy pattern with 3 other insiders in 14 days.

Samsara BioCapital GP, LLC, a 10% owner, purchased 600,000 shares at $13.50, adding $8,100,000.00 in capital and raising its stake by 11.8% to 5,674,916 shares. The purchase occurred as the stock traded 5.0% below its 52-week high of $14.96 and has gained 38.9% in the preceding 30 days and 15.1% over 90 days. The same insider's prior MLYS purchase on 2024-02-12 achieved a 90-day return of 0.2%, indicating mixed prior execution at this ticker. Notably, 3 other insiders also bought within the past 14 days, forming a cluster buy pattern. However, the company remains unprofitable with a net income of $-56,342,000.00, which constrains confidence in fundamental support for the buying activity.

10% owner Samsara BioCapital bought 48,770 shares (48.8K) totaling $1,259,622.58 ($1.3M) at blended avg $25.83; part of cluster buy pattern

Samsara BioCapital GP, LLC executed 4 separate purchases totaling 48,770 shares for $1,259,622.58 on 2024-11-26, increasing its holding to 1,717,127 shares post-transaction. The filing coincides with a cluster buy pattern: 2 other insiders also purchased within the past 14 days. Stock has declined -63.9% from its 52-week high of $71.53 and -43.8% over the past 30 days, trading near the blended purchase price of $25.83. The company remains unprofitable (net income $-20,217,000.00 for latest quarter; negative net income for full fiscal year) with zero latest-quarter revenue, elevating execution risk. Samsara's cross-ticker track record shows 75.00% win rate and +46.7% average 90-day return on prior buys, but this metric spans multiple tickers and does not indicate same-ticker conviction or timing accuracy at Neurogene.